Ontology highlight
ABSTRACT:
SUBMITTER: Snead JL
PROVIDER: S-EPMC2765681 | biostudies-literature | 2009 Oct
REPOSITORIES: biostudies-literature
Snead Jennifer L JL O'Hare Thomas T Adrian Lauren T LT Eide Christopher A CA Lange Thoralf T Druker Brian J BJ Deininger Michael W MW
Blood 20090825 16
Pioneering work with the Bcr-Abl inhibitor, imatinib, demonstrated a requirement for constant Bcr-Abl inhibition to achieve maximal therapeutic benefit in treating chronic myeloid leukemia (CML), establishing a paradigm that has guided further drug development for this disease. Surprisingly, the second-generation Bcr-Abl inhibitor, dasatinib, was reported to be clinically effective with once-daily dosing, despite a short (3- to 5-hour) plasma half-life. Consistent with this observation, dasatini ...[more]